PRP was prepared from autologous blood. PRP was prepared by refrigerating a total of 8 ml of blood taken
from the patient relative into a sterile citrated PRP tube. After centrifuging at +4 degrees Celsius, 2500 rpm,
and 8 minutes, the lower 1/3 of the plasma formed in the tube was withdrawn into a 2.5 ml injector, totaling
1 ml of PRP. 0.5 ml of Bevacizumab was added to the syringe containing 1 ml of citrated PRP. A total of 1.5 ml
of citrate, PRP and AntiVEGF mixture was injected into the left subtenon space under topical anesthesia.
Immediately after the subtenon injection, the patient was fitted with a MagnovisionTM electromagnetic
iontophoresis helmet. Magnovision is a stimulator and iontophoresis device specifically designed for
retina/optic nerve diseases, which contains 9 coils and generates a 2000 mG magnetic field with a 42 Hertz
vibration frequency that synchronously stimulates the bulbus, visual pathways and occipital cortex. These
parameters are fixed values ​​by the manufacturer that cannot be changed for patient safety. Each session is
applied effectively and safely for 30 minutes. This process is repeated for 3 sessions in 2 months between 3
or 4 weeks interval.